Relay Therapeutics (RLAY)
(Delayed Data from NSDQ)
$6.48 USD
+0.12 (1.89%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $6.49 +0.01 (0.15%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RLAY 6.48 +0.12(1.89%)
Will RLAY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for RLAY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RLAY
Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
RLAY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 131.6% Upside in Relay Therapeutics, Inc. (RLAY): Can the Stock Really Move This High?
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
Relay Therapeutics, Inc. (RLAY) Moves 10.0% Higher: Will This Strength Last?
Other News for RLAY
Relay Therapeutics (RLAY) Gets a Buy from Stifel Nicolaus
Relay Therapeutics: A 'Concept' Stock
Largest Clinical-Stage Biotech Drug Stocks Declined 6%
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Analysts Offer Insights on Healthcare Companies: Addus Homecare (ADUS), Relay Therapeutics (RLAY) and BioNTech SE (BNTX)